Euroopa Liit - eesti - EMA (European Medicines Agency)

biomarin international limited - sapropterin dihüdrokloriid - fenüülketonuria - muud alimentary seedetrakti ja ainevahetust tooted, - kuvan on näidustatud hüperfenüülalanineemia (hpa) raviks täiskasvanutel ja igas vanuses fenüülketonuuria (pku) lastel, kes teadaolevalt arvestama sellise ravi. kuvan on näidustatud ka ravi hyperphenylalaninaemia (hpa) täiskasvanud ja pediaatriliste patsientide igas vanuses koos tetrahydrobiopterin (bh4) puudulikkus, kes on osutunud tundlik, et selline kohtlemine.

Eesti - eesti - Ravimiamet

vitaflo international ltd. - toitained ilma fenüülalaniinita - pulber - 25g n30

Eesti - eesti - Ravimiamet

vitaflo international ltd. - toitained ilma fenüülalaniinita - pulber - 20g n30

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

biomarin international limited - pegvaliase - fenüülketonuria - muud seedetrakti ja ainevahetustooted - palynziq on näidustatud ravi patsientidel, kellel on fenüülketonuuria (pku) vähemalt 16-aastased ja vanemad, kes on ebapiisav vere fenüülalaniini kontrolli (vere fenüülalaniini taseme üle 600 micromol/l) vaatamata enne juhtimine on kättesaadav ravi valikud.

Euroopa Liit - eesti - EMA (European Medicines Agency)

eurocept international b. v. - naatrium phenylbutyrate - karbamoüül-fosfaadi synthase ma puudus haiguse - erinevate alimentary seedetrakti ja ainevahetust tooted - ravi kroonilise juhtimise uurea tsükli häired.

Euroopa Liit - eesti - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterin dihüdrokloriid - fenüülketonuria - muud alimentary seedetrakti ja ainevahetust tooted, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - inimese rotaviirus, elus nõrgestatud - immunization; rotavirus infections - vaktsiinid - rotarix on näidustatud 6 kuni 24 nädala vanuste imikute aktiivseks immuniseerimiseks rotaviiruse infektsiooni põhjustatud gastroenteriidi ennetamiseks. kasutada rotarix aluseks peaks olema euroopa liidu soovitus.

Euroopa Liit - eesti - EMA (European Medicines Agency)

takeda manufacturing austria ag - octocog alfa - hemofiilia a. - antihemorraagilised ained - verejooksu ravi ja profülaktika hemofiilia a patsientidel (kaasasündinud faktor viii puudulikkus). advate ei sisalda von willebrand tegur farmakoloogilised tõhus kogused ja ei ole seega näidustatud von willebrand haigus.

Eesti - eesti - Ravimiamet

milupa gmbh - toitained ilma fenüülalaniinita - pulber - 500g